Arye Weigensberg - Cronos Senior Development
| CRON Stock | USD 2.05 0.04 1.99% |
Executive
Arye Weigensberg is Senior Development of Cronos Group
| Age | 41 |
| Address | 111 Peter Street, Toronto, ON, Canada, M5V 2H1 |
| Phone | 416 504 0004 |
| Web | https://www.thecronosgroup.com |
Arye Weigensberg Latest Insider Activity
Tracking and analyzing the buying and selling activities of Arye Weigensberg against Cronos stock is an integral part of due diligence when investing in Cronos. Arye Weigensberg insider activity provides valuable insight into whether Cronos is net buyers or sellers over its current business cycle. Note, Cronos insiders must abide by specific rules, including filing SEC forms every time they buy or sell Cronos'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Arye Weigensberg over six months ago Acquisition by Arye Weigensberg of 72 shares of Cronos subject to Rule 16b-3 |
Cronos Management Efficiency
The company has return on total asset (ROA) of (0.0373) % which means that it has lost $0.0373 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0529) %, meaning that it created substantial loss on money invested by shareholders. Cronos' management efficiency ratios could be used to measure how well Cronos manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of November 2024, Return On Tangible Assets is likely to grow to -0.06. In addition to that, Return On Capital Employed is likely to drop to -0.08. At this time, Cronos' Non Current Assets Total are very stable compared to the past year. As of the 22nd of November 2024, Other Current Assets is likely to grow to about 6.5 M, while Total Assets are likely to drop about 808.6 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Nathalie Batten | OrganiGram Holdings | N/A | |
| Nyree Pinto | Tilray Inc | N/A | |
| Matthew Husson | SNDL Inc | 43 | |
| Neil Belot | Aurora Cannabis | N/A | |
| Deanna Garand | SNDL Inc | 41 | |
| Michelle Lefler | Aurora Cannabis | N/A | |
| Mitchell JD | Tilray Inc | 58 | |
| Dave Aird | Aurora Cannabis | N/A | |
| Chris Edwards | Canopy Growth Corp | N/A | |
| Thomas IV | Canopy Growth Corp | 35 | |
| Alex Miller | Aurora Cannabis | N/A | |
| Jenny Brewer | Canopy Growth Corp | N/A | |
| Roger Savell | Tilray Inc | 62 | |
| Phillip Shaer | Canopy Growth Corp | 46 | |
| Helen Martin | OrganiGram Holdings | 46 | |
| Darryl Vleeming | Aurora Cannabis | N/A | |
| Debra Wilson | Aurora Cannabis | N/A | |
| Alberto ParederoQuiros | SNDL Inc | 51 | |
| John Sadler | Tilray Inc | N/A | |
| Christelle LLB | Canopy Growth Corp | 42 | |
| Megan McCrae | OrganiGram Holdings | N/A | |
Management Performance
| Return On Equity | -0.0529 | ||||
| Return On Asset | -0.0373 |
Cronos Group Leadership Team
Elected by the shareholders, the Cronos' board of directors comprises two types of representatives: Cronos inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cronos. The board's role is to monitor Cronos' management team and ensure that shareholders' interests are well served. Cronos' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cronos' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Arye Weigensberg, Senior Development | ||
| Shayne Laidlaw, Director Strategy | ||
| James III, Controller VP | ||
| Terry Doucet, General Secretary | ||
| Kevin Gifford, VP Fin | ||
| James Holm, Chief Officer | ||
| Anna Shlimak, Senior Strategy | ||
| Michael JD, CEO President | ||
| Shannon Buggy, Senior People | ||
| Carlos Cortez, Controller VP | ||
| Adam Wagner, Senior Israel | ||
| Jeffrey Jacobson, Vice President - Business Development |
Cronos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cronos a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0529 | ||||
| Return On Asset | -0.0373 | ||||
| Profit Margin | (0.56) % | ||||
| Operating Margin | (0.54) % | ||||
| Current Valuation | (95.96 M) | ||||
| Shares Outstanding | 382.3 M | ||||
| Shares Owned By Insiders | 46.40 % | ||||
| Shares Owned By Institutions | 15.61 % | ||||
| Number Of Shares Shorted | 3.9 M | ||||
| Price To Earning | 36.41 X |
Pair Trading with Cronos
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cronos position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cronos will appreciate offsetting losses from the drop in the long position's value.Moving together with Cronos Stock
| 0.64 | VALN | Valneva SE ADR Downward Rally | PairCorr |
Moving against Cronos Stock
| 0.58 | GILD | Gilead Sciences | PairCorr |
| 0.57 | BMY | Bristol Myers Squibb | PairCorr |
| 0.43 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.31 | VRDN | Viridian Therapeutics | PairCorr |
The ability to find closely correlated positions to Cronos could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cronos when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cronos - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cronos Group to buy it.
The correlation of Cronos is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cronos moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cronos Group moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cronos can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cronos Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cronos. If investors know Cronos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cronos listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.144 | Earnings Share (0.12) | Revenue Per Share 0.267 | Quarterly Revenue Growth 0.46 | Return On Assets (0.04) |
The market value of Cronos Group is measured differently than its book value, which is the value of Cronos that is recorded on the company's balance sheet. Investors also form their own opinion of Cronos' value that differs from its market value or its book value, called intrinsic value, which is Cronos' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cronos' market value can be influenced by many factors that don't directly affect Cronos' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cronos' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cronos is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cronos' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.